In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy.
about
The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disordersThe why and wherefore of hepatic encephalopathyHepatic Encephalopathy: From the Pathogenesis to the New Treatments.Modulation of neural activation following treatment of hepatic encephalopathy.Cerebral oedema is not responsible for motor or cognitive deficits in rats with hepatic encephalopathy.Resting-state functional magnetic resonance imaging in hepatic encephalopathy: current status and perspectives.PET and MR imaging of neuroinflammation in hepatic encephalopathy.Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathyAcute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation.Aberrant resting-state corticostriatal functional connectivity in cirrhotic patients with hyperintense globus pallidus on T1-weighted MR imaging.A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation.Identification of minimal hepatic encephalopathy in patients with cirrhosis based on white matter imaging and Bayesian data mining.The diagnosis and treatment of minimal hepatic encephalopathyHepatic encephalopathy: an updated approach from pathogenesis to treatmentIn vivo evidence for microglial activation in neurodegenerative dementia.The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging.Positron emission tomography imaging of neuroinflammation.(18)F-DPA-714 PET Imaging for Detecting Neuroinflammation in Rats with Chronic Hepatic Encephalopathy.Imaging microglial activation during neuroinflammation and Alzheimer's disease.Pathogenesis and diagnosis of hepatic encephalopathy.Hepatic encephalopathy: a central neuroinflammatory disorder?Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.Hyponatremia in Patients with Cirrhosis of the Liver.Hepatic encephalopathy in dogs and cats.Neurotoxicity of Ammonia.Alcohol and Alzheimer's Disease-Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease?Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET studyReducing Peripheral Inflammation with Infliximab Reduces Neuroinflammation and Improves Cognition in Rats with Hepatic Encephalopathy.Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction.Infliximab reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the cerebellum and improves learning and motor coordination in rats with hepatic encephalopathy.Rats with minimal hepatic encephalopathy due to portacaval shunt show differential increase of translocator protein (18 kDa) binding in different brain areas, which is not affected by chronic MAP-kinase p38 inhibition.Ammonia inhibits long-term potentiation via neurosteroid synthesis in hippocampal pyramidal neurons.Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited.What we know: the inflammatory basis of hepatic encephalopathy.The Cerebellum of Patients with Steatohepatitis Shows Lymphocyte Infiltration, Microglial Activation and Loss of Purkinje and Granular Neurons.
P2860
Q24641816-8272263E-A0D7-4644-BB6C-77094F7D1261Q26771507-533F31E0-4CAA-4CE6-B200-3288035EBF9AQ30381016-0CE76876-1CDC-465B-AC58-510FA8CDA588Q30591625-A5919845-95AA-449B-BEFC-C6CADF0A5708Q30656195-163AF3AD-F4C8-4D70-9862-ED7640F2DD20Q30762483-52F6F435-0754-4325-96CF-B3FFEAEE87C9Q30878855-C73B5F7D-3EA9-4EAE-B399-ED9B5FA5A66CQ31041832-228E379C-8888-4C41-84B1-E3A4AEF93304Q34341513-B234A3B5-112D-4F83-A12F-7634DEFD301CQ34473681-DE7F0E8F-BD10-4627-8CB6-AE1580DC4290Q34635445-A584CCED-A1A4-4AD6-92AD-F118F10657E0Q35513402-FE5E1E68-FAC5-45CB-9D32-57CE1134E612Q35865294-CB927DB1-A632-487C-9E9D-5A65C9DFC7B6Q36473777-FF651D86-59FA-4FDE-839F-DA7212ACC3D9Q36546535-943B412D-3B20-45D5-A5D5-0A9C6649E12AQ36677808-CC8E750A-E973-4837-BC8B-86CACAFED89FQ36864320-F52B5ECD-D8B3-4F2A-8BE6-3D79FB382AC0Q36970398-29421012-3822-42A8-B30C-559425F2139EQ37340359-3B435C71-97E7-4E43-BA23-5628ABC73DF2Q37763086-F76DDC21-7E6B-4A63-845E-FFFCA172AFBBQ37863650-B73D1233-2698-4B35-8623-7C123F5A6469Q37945753-67FB430A-990B-4BFD-8ACF-C908C9E2D3EAQ38559606-B7A677B1-B828-48D1-81AF-5AEBBC79F851Q38802895-9A990BB1-CD20-4A9D-8220-0585DEE9803BQ38910515-74D2A365-3731-4521-B597-3FA2A14EF900Q39028577-F6364DB0-9546-422B-B97E-7FDB28AEEA01Q39029440-244EEBBD-E3A8-4F32-AF3F-E6297F980D04Q39182053-A613D407-3D2B-407C-B4CE-CD6CF5F1A7E5Q40832637-A1B73E43-BA52-4B7F-AC60-17E265F22CF0Q41085679-5ABD9716-FEEC-4BB3-9EB9-D763C5E09180Q42725641-CAEA11F6-42A6-47C9-9F69-AA900EAF9584Q43156054-D66F1273-6054-43B1-96AB-8FC840DA6E90Q52147303-A410729D-EBD1-4926-869E-93D24039FB11Q52147599-F8C9CC20-88C7-4A8A-BEBD-DCF4B3E254EAQ55287599-D807FDCD-2DBD-46DA-AEA3-A7E2300CA067
P2860
In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
In vivo imaging of cerebral "p ...... s with hepatic encephalopathy.
@ast
In vivo imaging of cerebral "p ...... s with hepatic encephalopathy.
@en
type
label
In vivo imaging of cerebral "p ...... s with hepatic encephalopathy.
@ast
In vivo imaging of cerebral "p ...... s with hepatic encephalopathy.
@en
prefLabel
In vivo imaging of cerebral "p ...... s with hepatic encephalopathy.
@ast
In vivo imaging of cerebral "p ...... s with hepatic encephalopathy.
@en
P2093
P2860
P356
P1433
P1476
In vivo imaging of cerebral "p ...... s with hepatic encephalopathy.
@en
P2093
D M Forton
R B Banati
S D Taylor-Robinson
P2860
P304
P356
10.1136/GUT.2005.075051
P407
P577
2005-10-06T00:00:00Z